Teva Pharma (TEVA) Receives CRL from FDA for SD-809; No New Trials Requested
Tweet Send to a Friend
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has received a Complete Response Letter (CRL) from the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE